Jazz Pharmaceuticals Inc.

Company overview. Jazz Pharmaceuticals, Inc. is the principal U.S. operating subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a specialty biopharmaceutical company headquartered at Waterloo Exchange, Dublin 4, Ireland, with U.S. operations including R&D and commercial functions in California and Pennsylvania. The original Jazz Pharmaceuticals was founded in 2003; in 2012 it combined with Azur Pharma, which was renamed Jazz Pharmaceuticals plc and became the parent, with Jazz Pharmaceuticals, Inc. as a wholly owned subsidiary. It is publicly traded on Nasdaq with roughly 2,800–2,900 employees and FY2025 total revenue of about $4.3 billion, per company results.

Products / operations. Jazz develops and commercializes prescription medicines in neuroscience (sleep and epilepsy) and oncology. Key marketed products include Xywav (low-sodium oxybate) for narcolepsy and idiopathic hypersomnia and Xyrem (sodium oxybate); Epidiolex/Epidyolex (cannabidiol) for seizures; and oncology products Rylaze/Enrylaze (asparaginase), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), Defitelio, and Modeyso (dordaviprone), added via the 2025 acquisition of Chimerix. It also earns royalties on authorized generic high-sodium oxybate.

Patent-litigation posture. Jazz is an operating company and an active two-way litigant: 59 tracked cases as plaintiff and 39 as defendant. As plaintiff it enforces its branded patents against generic and competing entrants — most notably a long-running series against Avadel CNS Pharmaceuticals over oxybate distribution/REMS patents for Xyrem and Xywav, filed in the District of Delaware. As defendant it faces payer antitrust and consumer class actions over Xyrem (Blue Cross & Blue Shield of Florida; New York State Teamsters Council Health & Hospital Fund) and Avadel's declaratory-judgment actions. Tracked venues cluster in D. Del., D.N.J., and N.D. Cal. — not the Eastern District of Texas.

Notable context. Prominent dockets include the Jazz–Avadel oxybate patent suits and the Xyrem antitrust litigation, plus a False Claims Act qui tam matter (United States ex rel. Leonardo Sorgi). Jazz has reported settling most major litigation, including Epidiolex ANDA disputes.